Home/Kyverna Therapeutics/Timothy Springer, PhD
TS

Timothy Springer, PhD

Chair of the Board of Directors

Kyverna Therapeutics

Kyverna Therapeutics Pipeline

DrugIndicationPhase
KYV-101Lupus Nephritis (Systemic Lupus Erythematosus)Phase 1/2
KYV-201Undisclosed autoimmune indicationPreclinical